A tweak or an outrage? Germany passes new pricing law
This article was originally published in Scrip
Germany has officially passed its contentious new drug pricing law, which imposes an extended price freeze, scraps retrospective AMNOG assessments, reduces mandatory discounts from 16% to 7% and most controversially of all clarifies that parts of the German system will use confidential rebated prices as the "official" price as opposed to list prices. To some, this last, relatively small aspect of the law is a violation of the constitution, while others say the debate surrounding this tweak to the law has been blown out of proportion.